CLGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CollPlant Biotechnologies Ltd (CLGN) is not a good buy for a beginner investor with a long-term focus at this time. The company faces significant financial challenges, including declining revenue, negative earnings, and a risk of delisting from Nasdaq. Additionally, there are no strong positive catalysts or trading signals to suggest immediate upside potential. The technical indicators are neutral, and the stock lacks momentum for a strong recovery. It is advisable to hold off on investing until there is a clearer path to financial stability and growth.
The MACD histogram is positive at 0.0388, indicating slight bullish momentum, but it is contracting. RSI is neutral at 52.537, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing indecision in the price trend. Key support is at 0.585, and resistance is at 0.792. Overall, the technical indicators are neutral with no strong buy signals.
CollPlant's revenue was driven by a milestone payment from AbbVie and expansion of its distribution network in North America.
The company received a Nasdaq non-compliance notice due to its share price being below $1.00, risking delisting. Financial performance in Q4 2025 showed significant declines in revenue (-63.41% YoY), net income (-17.30% YoY), and EPS (-26.47% YoY). Analyst Jason Kolbert downgraded the stock to Hold, citing concerns over recent financing and investor sentiment.
In Q4 2025, revenue dropped by 63.41% YoY to $60,000. Net income decreased by 17.30% YoY to -$3.2 million. EPS fell by 26.47% YoY to -$0.25. Gross margin improved significantly but remains negative at -220%. Overall, the company is struggling with profitability and growth.
Analyst Jason Kolbert from D. Boral Capital downgraded the stock to Hold from Buy, citing concerns over recent financing and its impact on investor sentiment. No price target was provided.
